28 results on '"Rizzo P."'
Search Results
2. EP.11A.23 REAL-IMPACT: Real-World Effectiveness of Immunotherapy in PD-L1 Negative Advanced NSCLC - A Multicenter Cohort Study in Argentina
3. P4.11E.25 NSCLC Immune Hemogram Index (NIHX) A Predictive Score for Immunotherapy Response in PD-L1 Negative Advanced NSCLC
4. MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.
5. EP08.02-097 Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina
6. EP08.03-007 Spontaneous Regression in Metastatic Non-small Cell Lung Cancer: A Case Report
7. EP16.02-029 Plasma-Based Next Generation Sequencing for Molecular Characterization of Lung Adenocarcinoma: A Multicentric Cohort From Argentina
8. P84.22 Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina
9. P01.11 Clinical Outcomes After Discontinuation of Immunotherapy in Patients With Non-Progressing Metastatic Lung Cancer
10. P33.15 TMB in the First-Line Setting of NSCLC: A Systematic Review with Indirect Comparisons Between PD-1 and PD-L1 Inhibitors
11. P2.25 Immunotherapy at Any Line of Treatment Improves Survival in Hispanic Patients with Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Compared with Chemotherapy (Quijote-CLICaP)
12. P2.23 Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy
13. P1.04-82 Toxicity as a Clinical Marker for Efficacy of Immunotherapy in NSCLC: A Multicentric Experience from Argentina
14. P2.04-82 Discontinuation of Anti-PD-1/PD-L1 Antibody Therapy in the Absence of Disease Progression: Clinical Outcomes in Advanced NSCLC
15. P1.16-10 Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
16. EP1.04-46 Immunotherapy at Any Line Improves Survival in Hispanic Patients with Advanced Metastatic NSCLC Compared to Chemotherapy (Quijote-CLICaP)
17. P07.02 Detection of Molecular Residual Disease (MRD) using ctDNA in NSCLC: A Systematic Review and Meta-Analysis
18. P48.10 Chemo-Immunotherapy in the Frontline of Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Indirect Comparisons
19. P21.13 Durvalumab in Locally-Advanced NSCLC in LATAM: Real World Data from Patients Included in the Early Access Program
20. P1.04-81 Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy
21. P2.04-81 Non-Small Cell Lung Cancer Treated with Immunotherapy: Multi-Institutional Experience from Argentina
22. EP1.04-41 Efficacy of Immunotherapy in Elderly Patients with Non-Small Cell Lung Cancer: A Multicentric Experience from Argentina
23. P2.38: Nivolumab in Clinical Practice: Real World Experience in an Argentina Oncologic Center
24. P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients
25. P1.13-16 The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis
26. OA 07.05 Serial Biopsies in Patients with EGFR-Mutant NSCLC Highlight the Spatial and Temporal Heterogeneity of Resistance Mechanisms
27. P1.01-058 Real World Data with Nivolumab: Experience in Argentina
28. P2.12: Treatment Response in Patients With ALK Immunohistochemistry (IHC) Positive With Fish Negative
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.